GCP(TM) Study Published in Urology Journal

Effects of GCP Tested On Prostate Cancer Patients

RYE, NY, May 5, 2004 -- A pilot study on Genistein Combined Polysaccharide (GCP) titled, "Effects of a Genistein-Rich Extract on PSA Levels in Men With a History of Prostate Cancer," was recently published in the journal Urology. The published study was conducted by Ralph W. deVere White, M.D., Department of Urology, University of California Davis, School of Medicine, and associates.

The purpose of this study was to determine whether supplemental amounts of GCP would reduce prostate-specific antigen (PSA) levels in patients with prostate cancer by at least 50 percent. The study examined 52 men with prostate cancer who took GCP three times daily for 6 months.

"Carcinoma of the prostate is the most common cancer diagnosis in American men," stated Buxiang Sun, M.D., Ph.D., Amino Up Chemical Co., Ltd. "Due to the increased number of diagnosed patients turning to complementary and alternative treatment methods and based on previous research that found GCP to have positive anticancer effects, we felt it necessary to look further into the efficacy of GCP in treating this ailment."

By the end of the 6-month treatment period, eight patients recorded PSA reductions with one of them exhibiting a decline in PSA of greater than 50 percent. Researchers observed that all patients with notable PSA response at 6 months had opted for watchful waiting as opposed to first-line therapy. Further analysis showed an overall decline in PSA levels among these men in comparison with those in active treatment groups. However, eight of 13 evaluated patients in the active surveillance group were able to stabilize PSA levels. Therefore, more study is warranted for those choosing active surveillance.

GCP is an extract produced by a special soybean fermentation technique involving isoflavone extracts and medicinal mushrooms. GCP contains rich levels of isoflavone aglycones, especially genistein, as well as polysaccharides from basidiomycetes mushrooms. Numerous research studies have shown that GCP inhibits angiogenesis and cell proliferation. GCP is well tolerated by the body with no known serious side effects and is highly bioavailable for use by the body.

For more information on GCP, visit the GCP Research Association Web site at www.GCPresearch.com or call 914.251.0255. If you are interested in receiving a copy of the study, contact Natalie Taylor at [email protected] or 801.538.0777 ext.107.

# # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.